ABVX – Abivax ADR
ABVX — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
4.99
Margin Of Safety %
Put/Call OI Ratio
0.47
EPS Next Q Diff
0.45
EPS Last/This Y
2.14
EPS This/Next Y
0.39
Price
102.49
Target Price
146.27
Analyst Recom
1.39
Performance Q
-29.48
Upside
-284.8%
Beta
1.85
Ticker: ABVX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | ABVX | 109.59 | 0.58 | 0.26 | 47125 |
| 2026-03-10 | ABVX | 115.27 | 0.58 | 0.29 | 48428 |
| 2026-03-11 | ABVX | 112.2 | 0.57 | 0.27 | 49501 |
| 2026-03-12 | ABVX | 116.99 | 0.57 | 0.17 | 50208 |
| 2026-03-13 | ABVX | 116.98 | 0.57 | 0.17 | 50208 |
| 2026-03-17 | ABVX | 126.66 | 0.55 | 0.38 | 55271 |
| 2026-03-18 | ABVX | 124.02 | 0.52 | 0.49 | 56359 |
| 2026-03-19 | ABVX | 122.99 | 0.52 | 0.35 | 57956 |
| 2026-03-20 | ABVX | 120.41 | 0.52 | 0.51 | 61006 |
| 2026-03-23 | ABVX | 115.02 | 0.45 | 0.93 | 52849 |
| 2026-03-24 | ABVX | 110.12 | 0.44 | 0.29 | 54945 |
| 2026-03-25 | ABVX | 110.64 | 0.43 | 0.36 | 60938 |
| 2026-03-26 | ABVX | 109.5 | 0.44 | 1.34 | 61731 |
| 2026-03-27 | ABVX | 102.47 | 0.47 | 0.85 | 64554 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | ABVX | 109.64 | - | - | -4.42 |
| 2026-03-10 | ABVX | 115.15 | - | - | -4.42 |
| 2026-03-11 | ABVX | 112.21 | - | - | -4.42 |
| 2026-03-12 | ABVX | 116.94 | - | - | -4.42 |
| 2026-03-13 | ABVX | 115.66 | - | - | -4.42 |
| 2026-03-17 | ABVX | 126.68 | - | - | -4.42 |
| 2026-03-18 | ABVX | 124.02 | - | - | -4.42 |
| 2026-03-19 | ABVX | 122.90 | - | - | -4.42 |
| 2026-03-20 | ABVX | 120.50 | - | - | -4.42 |
| 2026-03-23 | ABVX | 115.05 | - | - | -4.42 |
| 2026-03-24 | ABVX | 110.14 | - | - | -4.42 |
| 2026-03-25 | ABVX | 110.66 | - | - | -4.42 |
| 2026-03-26 | ABVX | 109.50 | - | - | -4.42 |
| 2026-03-27 | ABVX | 102.49 | - | - | -3.46 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | ABVX | 0.00 | -1.74 | 4.78 |
| 2026-03-10 | ABVX | 0.00 | -1.74 | 4.78 |
| 2026-03-11 | ABVX | 0.00 | -1.74 | 4.93 |
| 2026-03-12 | ABVX | 0.00 | -1.74 | 4.92 |
| 2026-03-13 | ABVX | 0.00 | -1.74 | 4.92 |
| 2026-03-17 | ABVX | 0.00 | -2.86 | 4.92 |
| 2026-03-18 | ABVX | 0.00 | -2.86 | 4.92 |
| 2026-03-19 | ABVX | 0.00 | -2.86 | 4.92 |
| 2026-03-20 | ABVX | 0.00 | -2.86 | 4.92 |
| 2026-03-23 | ABVX | 0.00 | -2.08 | 4.92 |
| 2026-03-24 | ABVX | 0.00 | -2.08 | 4.92 |
| 2026-03-25 | ABVX | 0.00 | -2.08 | 4.99 |
| 2026-03-26 | ABVX | 0.00 | -2.08 | 4.99 |
| 2026-03-27 | ABVX | 0.00 | -2.08 | 4.99 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.19
Avg. EPS Est. Current Quarter
-0.81
Avg. EPS Est. Next Quarter
-0.74
Insider Transactions
Institutional Transactions
-2.08
Beta
1.85
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
15
Growth Score
22
Sentiment Score
10
Actual DrawDown %
31.1
Max Drawdown 5-Year %
Target Price
146.27
P/E
Forward P/E
PEG
P/S
P/B
15.05
P/Free Cash Flow
EPS
-5.41
Average EPS Est. Cur. Y
-3.46
EPS Next Y. (Est.)
-3.08
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
1.42
Return on Equity vs Sector %
-101.2
Return on Equity vs Industry %
-84.9
EPS 1 7Days Diff
-0.2
EPS 1 30Days Diff
-0.18
EBIT Estimation
◆
ABVX
Healthcare
$102.47
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
34.4
Range 1M
2.7%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
31.2%
EPS NY
18.4%
52W%
68%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+42.7% upside
Upside
+42.7%
Quality
15
Abivax SASector: Healthcare
Industry: Biotechnology
Employees:
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
ABVX
Latest News
—
Caricamento notizie per ABVX…
stock quote shares ABVX – Abivax ADR Stock Price stock today
news today ABVX – Abivax ADR stock forecast ,stock prediction 2023 2024 2025
marketwatch ABVX – Abivax ADR yahoo finance google finance
stock history ABVX – Abivax ADR invest stock market
stock prices ABVX premarket after hours
ticker ABVX fair value insiders trading